Published in Eur Urol on August 04, 2009
Urothelial signaling. Physiol Rev (2013) 2.56
Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract (2013) 1.61
Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol (2012) 1.06
Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model. Sci Rep (2013) 0.98
Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions. Am J Physiol Renal Physiol (2013) 0.90
Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health (2013) 0.90
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag (2013) 0.90
Dietary macronutrient and energy intake and urinary incontinence in women. Am J Epidemiol (2010) 0.86
Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity? Br J Clin Pharmacol (2011) 0.83
Pharmacological treatment of chronic pelvic ischemia. Ther Adv Urol (2014) 0.82
Urothelial mucosal signaling and the overactive bladder-ICI-RS 2013. Neurourol Urodyn (2014) 0.82
Intakes of vitamins and minerals in relation to urinary incontinence, voiding, and storage symptoms in women: a cross-sectional analysis from the Boston Area Community Health survey. Eur Urol (2011) 0.80
New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol (2015) 0.80
Dietary macronutrient intake and lower urinary tract symptoms in women. Ann Epidemiol (2011) 0.79
Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. Sci Rep (2014) 0.78
Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. World J Mens Health (2015) 0.78
Editorial comment on: A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 0.77
New therapeutic strategies for the treatment of male lower urinary tract symptoms. Res Rep Urol (2016) 0.77
Changes in nerve-mediated contractility of the lower urinary tract in a mouse model of premature ageing. Br J Pharmacol (2014) 0.76
Development of an Improved Animal Model of Overactive Bladder: Transperineal Ligation versus Transperitoneal Ligation in Male Rats. World J Mens Health (2016) 0.75
Non-Hormonal treatment of BPH/BOO. Indian J Urol (2014) 0.75
The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction. Ther Adv Urol (2016) 0.75
Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. World J Urol (2013) 0.75
Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review. Int Urogynecol J (2016) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol (2007) 3.61
Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol (2008) 3.09
Defining a patient-reported outcome measure for urethral stricture surgery. Eur Urol (2011) 3.00
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol (2007) 2.84
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int (2009) 2.63
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Urothelial signaling. Physiol Rev (2013) 2.56
Tissue-engineered buccal mucosa urethroplasty-clinical outcomes. Eur Urol (2008) 2.44
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
A prospective patient-centred evaluation of urethroplasty for anterior urethral stricture using a validated patient-reported outcome measure. Eur Urol (2013) 2.29
Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol (2004) 2.23
Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol (2007) 2.21
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol (2006) 2.19
Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol (2009) 2.19
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology (2010) 2.19
The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13
Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11
EAU guidelines on urinary incontinence. Eur Urol (2010) 2.10
Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks. Eur Urol (2009) 2.04
Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 2.01
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol (2006) 1.94
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Assessment of basic endoscopic performance using a virtual reality simulator. J Am Coll Surg (2002) 1.86
Muscarinic receptor antagonists for overactive bladder. BJU Int (2007) 1.81
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
Plasma vaporisation of the prostate: initial clinical results. Eur Urol (2009) 1.80
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology (2003) 1.79
A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures. Eur Urol (2011) 1.79
Summary of the recommendations on sexual dysfunctions in men. J Sex Med (2004) 1.78
Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol (2003) 1.75
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74
Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol (2008) 1.73
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology (2012) 1.71
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71
Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol (2007) 1.70
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol (2007) 1.66
Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Urinary retention in women: its causes and management. BJU Int (2006) 1.64
Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology (2009) 1.61
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol Urodyn (2011) 1.60
Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59